Role of the maillard reaction in diabetes mellitus and diseases of aging

Drugs and Aging

Volumn 9, Issue 2, 1996, Pages 69-77

  Thorpe, Suzanne R ^a   Baynes, John W ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ANTIOXIDANT; CARBOHYDRATE; COLLAGEN; CRYSTALLIN; PROTEIN;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ATHEROSCLEROSIS; CONNECTIVE TISSUE; DIABETES MELLITUS; EDITORIAL; ELASTICITY; HUMAN; INFLAMMATION; LENS; LIFESTYLE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; TISSUE INJURY;

EID: 0029763759     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609020-00001     Document Type: Editorial

References (47)

1. Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Hebd Seances Acad Sci 1912; 154: 66-8
2. Cohen MP. Diabetes and protein glycosylation: measurement and biological relevance. New York: Springer-Verlag, 1986
3. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
4. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994; 124: 19-30
5. Baynes JW, Watkins NG, Fisher CI, et al. The Amadori product on protein. In: Baynes JW, Monnier VM, editors. The Maillard reaction in aging, diabetes, and nutrition. New York: Alan R. Liss, 1989: 43-67
6. Sell DR, Lapolla A, Odetti P, et al. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41: 1286-92
7. McCance DR, Dyer DG, Dunn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-8
8. Beisswenger PJ, Moore LL, Brinck-Johnsen T, et al. Increased collagen-linked pentosidine levels and advanced glycosylation end-products in early diabetic nephropathy. J Clin Invest 1993; 92: 2212-7
9. Fu MX, Wells-Knecht KJ, Blackledge JA, et al. Glycation, glycoxidation and crosslinking of collagen by glucose: kinetics, mechanisms and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676-83
10. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994; 91: 9441-5
11. e-(carboxymethyl)-lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-6
12. Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654-67
13. Baynes JW. The role of oxidative stress in the development of complications in diabetes. Diabetes 1991; 40: 405-12
14. Baynes JW. Role of oxidation chemistry in the Maillard reaction in vivo. In: Ikan R, editor. The Maillard reaction in biological systems. New York: John Wiley, 1995
15. Baynes JW. Reactive oxygen in the aetiology and complications of diabetes. In: Ioannides C, editor. Drugs, diet and disease. Vol. 2: Mechanistic approaches to diabetes. London: Pergamon Press, 1996
16. Thornalley PJ. The glyoxalase system: new developments toward functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990; 269: 1-11
17. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-9
18. Al-Abed Y, Liebich H, Voelter W, et al. Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein. J Biol Chem 1996; 271: 2892-6
19. Lyons TJ, Li W, Wells-Knecht MC, et al. Toxicity of mildly modified low density lipoprotein to cultured retinal capillary cells and pericytes. Diabetes 1994; 43: 1090-5
20. Bucala R, Makita Z, Koschinsky T, et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Nat Acad Sci U S A 1993; 90: 6436-8
21. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-7
22. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92
23. e-(carboxymethyl)lysine is a dominant advanced glycation end-product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-8
24. Makita Z, Vlassara H, Rayfield E, et al. Hemoglobin-AGE, a circulating marker of advanced glycosylation. Science 1992; 258: 651-3
25. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42
26. Papanastasiou P, Grass L, Rodela H, et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or continuous ambulatory peritoneal dialysis. Kidney Int 1994; 46: 216-22
27. Odetti P, Fogarty J, Sell DR, et al. Chromatographic quantitation of plasma and red cell pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-9
28. Hricik DE, Schulak JA, Sell DR, et al. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 1993; 43: 398-403
29. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-52
30. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521-8
31. Smith MA, Taneda A, Richey PL, et al. Advanced Maillard reaction endproducts are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994; 91: 5170-4
32. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994; 91: 7787-91
33. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994; 91: 4766-70
34. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97
35. Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14: 1521-8
36. Wautier JL, Wautier MP, Schmidt AM et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994; 91: 7742-6
37. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432-8
38. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: what role for oxidative stress? Metabolism 1995; 44: 363-8
39. Taneda S, Monnier VM. ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin Chem 1994; 40: 1766-73
40. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629-32
41. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular function by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221-32
42. Picard S, Parthasarathy S, Fruebis J, et al. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptor. Proc Natl Acad Sci U S A 1992; 89: 6876-80
43. Paolisso G, Scheen A, Lefebvre P. Glucose handling, diabetes and aging. Horm Res 1995; 43: 52-7
44. Yue DK, McLennan S, Handelsman DJ, et al. The effect of salicylates on nonenzymatic glycosylation and thermal stability of collagen in diabetic mice. Diabetes 1984; 33: 745-51
45. Yue DK, McLennan S, Handelsman DJ, et al. The effects of cyclooxygenase and lipoxygenase inhibitors on the collagen abnormalities in diabetic rats. Diabetes 1985; 34: 74-8
46. Yue TL, McKenna PJ, Gu JL, et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993; 22: 922-8
47. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62